Randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer (mCRC), comparing the efficacy and safety of XELIRI plus bevacizumab versus FOLFIRI plus bevacizumab (AXEPT)

被引：0
|
作者：
Kim, T. W. [1 ]
Park, Y. S. [2 ]
Muro, K. [3 ]
Xu, R. [4 ]
Han, S. [5 ]
Yamazaki, K. [6 ]
Wang, W. [7 ]
Ahn, J. B. [8 ]
Uetake, H. [9 ]
Deng, Y. [10 ]
Cho, S. [11 ]
Matsumoto, H. [12 ]
Ba, Y. [13 ]
Lee, K-W. [14 ]
Nishina, T. [15 ]
Zhang, T. [16 ]
Iwasa, S. [17 ]
Morita, S. [18 ]
Sakamoto, J. [19 ]
机构：
[1] Asan Med Ctr, Oncol, Seoul, South Korea
[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Hematol Oncol, Seoul, South Korea
[3] Aichi Canc Ctr Hosp, Clin Oncol, Nagoya, Aichi, Japan
[4] Sun Yat Sen Univ, Ctr Canc, Med Oncol, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[5] Seoul Natl Univ Hosp, Internal Med, Seoul, South Korea
[6] Shizuoka Canc Ctr, Gastrointestinal Oncol, Shizuoka, Japan
[7] First Peoples Hosp Foshan, Gastrointestinal Oncol, Foshan, Guangdong, Peoples R China
[8] Yonsei Univ, Severance Hosp, Internal Med, Seoul, South Korea
[9] Tokyo Med & Dent Univ, Grad Sch, Specialized Surg, Tokyo, Japan
[10] Sun Yat Sen Univ, Affiliated Hosp 6, Med Oncol, Guangzhou, Guangdong, Peoples R China
[11] Chonnam Natl Univ, Hematol Oncol, Hwasun Hosp, Jeollanamdo, South Korea
[12] Tokyo Metropolitan Canc & Infect Dis Komagome Hos, Surg, Tokyo, Japan
[13] Tianjin Med Univ Canc Inst & Hosp, Digest Oncol, Tianjin, Peoples R China
[14] Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seoul, South Korea
[15] Natl Hosp Org Shikoku Canc Ctr, Gastrointestinal Med Oncol, Matsuyama, Ehime, Japan
[16] Huazhong Univ Sci & Technol, Tongji Med Coll, Abdominal Oncol, Union Hosp, Wuhan, Hubei, Peoples R China
[17] Natl Canc Ctr, Gastrointestinal Med Oncol, Tokyo, Japan
[18] Kyoto Univ, Biomed Stat & Bioinformat, Grad Sch Med, Kyoto, Japan
[19] Tokai Cent Hosp, Kakamigahara, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3_PR
引用
收藏
页码：186 / 186
页数：1
相关论文
共 50 条
  • [1] A multinational, randomized, phase III trial of XELIRI ( plus bevacizumab) versus FOLFIRI ( plus bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).
    Muro, Kei
    Kim, Tae Won
    Park, Young Suk
    Uetake, Hiroyuki
    Nishina, Tomohiro
    Nozawa, Hiroaki
    Matsumoto, Hiroshi
    Yamazaki, Kentaro
    Han, Sae-Won
    Lee, Keun-Wook
    Deng, Yanhong
    Buyse, Marc E.
    Satoh, Taroh
    Ryoo, Baek-Yeol
    Shen, Lin
    Iwasa, Satoru
    Morita, Satoshi
    Sakamoto, Junichi
    Xu, Rui-hua
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [2] Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
    Kotaka, Masahito
    Xu, Ruihua
    Muro, Kei
    Park, Young Suk
    Morita, Satoshi
    Iwasa, Satoru
    Uetake, Hiroyuki
    Nishina, Tomohiro
    Nozawa, Hiroaki
    Matsumoto, Hiroshi
    Yamazaki, Kentaro
    Han, Sae-Won
    Wang, Wei
    Ahn, Joong Bae
    Deng, Yanhong
    Cho, Sang-Hee
    Ba, Yi
    Lee, Keun-Wook
    Zhang, Tao
    Satoh, Taroh
    Buyse, Marc E.
    Ryoo, Baek-Yeol
    Shen, Lin
    Sakamoto, Junichi
    Kim, Tae Won
    [J]. CHINESE JOURNAL OF CANCER, 2016, 35 : 102
  • [3] Study protocol of the Asian XELIRI ProjecT(AXEPT):a multinational,randomized,non-inferiority,phase Ⅲ trial of second-line chemotherapy for metastatic colorectal cancer, comparing the eicacy and safety of XELIRI with or without bevacizumab versus FOLFIRI w
    Masahito Kotaka
    Ruihua Xu
    Kei Muro
    Young Suk Park
    Satoshi Morita
    Satoru Iwasa
    Hiroyuki Uetake
    Tomohiro Nishina
    Hiroaki Nozawa
    Hiroshi Matsumoto
    Kentaro Yamazaki
    Sae-Won Han
    Wei Wang
    Joong Bae Ahn
    Yanhong Deng
    Sang-Hee Cho
    Yi Ba
    Keun-Wook Lee
    Tao Zhang
    Taroh Satoh
    Marc E.Buyse
    Baek-Yeol Ryoo
    Lin Shen
    Junichi Sakamoto
    Tae Won Kim
    [J]. 癌症, 2016, 35 (12) : 735 - 742
  • [4] A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT)
    Nakamura, Masato
    Kim, Tae Won
    Xu, Rui-hua
    Park, Young Suk
    Hong, Yong Sang
    Zhang, Tao
    Kato, Takeshi
    Cho, Sang Hee
    Wang, Wei
    Matsuoka, Hiroshi
    Han, Sae-Won
    Deng, Yanhong
    Makiyama, Akitaka
    Lee, Keun-Wook
    Ba, Yi
    Ota, Mitsuyoshi
    Iwasa, Satoru
    Morita, Satoshi
    Yamada, Yasuhide
    Muro, Kei
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [5] A comparison of efficacy of first-line chemotherapy regimens for metastatic colorectal cancer (mCRC): FOLFIRI plus bevacizumab vs. XELIRI plus bevacizumab
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 336 - 336
  • [6] Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial
    Xu, Rui-Hua
    Muro, Kei
    Morita, Satoshi
    Iwasa, Satoru
    Han, Sae Won
    Wang, Wei
    Kotaka, Masahito
    Nakamura, Masato
    Ahn, Joong Bae
    Deng, Yan-Hong
    Kato, Takeshi
    Cho, Sang-Hee
    Ba, Yi
    Matsuoka, Hiroshi
    Lee, Keun-Wook
    Zhang, Tao
    Yamada, Yasuhide
    Sakamoto, Junichi
    Park, Young Suk
    Kim, Tae Won
    [J]. LANCET ONCOLOGY, 2018, 19 (05): : 660 - 671
  • [7] Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
    Koeberle, D.
    Betticher, D. C.
    von Moos, R.
    Dietrich, D.
    Brauchli, P.
    Baertschi, D.
    Matter, K.
    Winterhalder, R.
    Borner, M.
    Anchisi, S.
    Moosmann, P.
    Kollar, A.
    Saletti, P.
    Roth, A.
    Frueh, M.
    Kueng, M.
    Popescu, R. A.
    Schacher, S.
    Hess, V.
    Herrmann, R.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (04) : 709 - 714
  • [8] Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Ueno, Masashi
    Yamamoto, Noriko
    Shinozaki, Eiji
    Mizunuma, Nobuyuki
    Yamaguchi, Toshiharu
    Hatake, Kiyohiko
    [J]. SURGERY TODAY, 2011, 41 (08) : 1067 - 1074
  • [9] Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients
    Mitsukuni Suenaga
    Satoshi Matsusaka
    Masashi Ueno
    Noriko Yamamoto
    Eiji Shinozaki
    Nobuyuki Mizunuma
    Toshiharu Yamaguchi
    Kiyohiko Hatake
    [J]. Surgery Today, 2011, 41 : 1067 - 1074
  • [10] A COMPARISON OF XELIRI PLUS BEVACIZUMAB WITH FOLFIRI PLUS BEVACIZUMAB AS FIRST-LINE SETTING IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ahmet, Bilici
    Uygun, Kazim
    Kaya, Serap
    Ustaalioglu, Bala Basak Oven
    Yildiz, Ramazan
    Temiz, Suleyman
    Seker, Mesut
    Aksu, Gorkem
    Cabuk, Devrim
    Gumus, Mahmut
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 98 - 99
12345